Transgene-free disease-specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes

Y.C. Kudva, S Ohmine, L.V. Greder, J R Dutton, A Armstrong, J.G. De Lamo, Y.K. Khan, T Thatava, M Hasegawa, N Fusaki, J Slack, Y Ikeda

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The induced pluripotent stem cell (iPSC) technology enables derivation of patient-specific pluripotent stem cells from adult somatic cells without using an embryonic cell source. Redifferentiation of iPSCs from diabetic patients into pancreatic islets will allow patient-specific disease modeling and autologous cell replacement therapy for failing islets. To date, diabetes-specific iPSCs have been generated from patients with type 1 diabetes using integrating retroviral vectors. However, vector integration into the host genome could compromise the biosafety and differentiation propensities of derived iPSCs. Although various integration-free reprogramming systems have been described, their utility to reprogram somatic cells from patients remains largely undetermined. Here, we used nonintegrating Sendai viral vectors to reprogram cells from patients with type 1 and type 2 diabetes (T2D). Sendai vector infection led to reproducible generation of genomic modification-free iPSCs (SV-iPSCs) from patients with diabetes, including an 85-year-old individual with T2D. SV-iPSCs lost the Sendai viral genome and antigens within 8-12 passages while maintaining pluripotency. Genome-wide transcriptome analysis of SV-iPSCs revealed induction of endogenous pluripotency genes and downregulation of genes involved in the oxidative stress response and the INK4/ARF pathways, including p16(INK4a), p15(INK4b), and p21(CIP1). SV-iPSCs and iPSCs made with integrating lentiviral vectors demonstrated remarkable similarities in global gene expression profiles. Thus, the Sendai vector system facilitates reliable reprogramming of patient cells into transgene-free iPSCs, providing a pluripotent platform for personalized diagnostic and therapeutic approaches for diabetes and diabetes-associated complications.
Original languageEnglish
Pages (from-to)451-461
Number of pages10
JournalStem Cells Translational Medicine
Volume1
Issue number6
DOIs
Publication statusPublished - Jun 2012

Fingerprint Dive into the research topics of 'Transgene-free disease-specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes'. Together they form a unique fingerprint.

  • Cite this

    Kudva, Y. C., Ohmine, S., Greder, L. V., Dutton, J. R., Armstrong, A., De Lamo, J. G., Khan, Y. K., Thatava, T., Hasegawa, M., Fusaki, N., Slack, J., & Ikeda, Y. (2012). Transgene-free disease-specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes. Stem Cells Translational Medicine, 1(6), 451-461. https://doi.org/10.5966/sctm.2011-0044